ARTICLE | Clinical News

Zadaxin fails second HCV Phase III

May 26, 2006 1:05 AM UTC

SciClone (SCLN) said Zadaxin plus pegylated interferon (IFN) alpha missed the primary endpoint of sustained virologic response (SVR) rate vs. IFN alpha and placebo in a Phase III trial to treat HCV infection in 500 patients with early cirrhosis of the liver who have failed prior therapy. In December, Zadaxin missed the co-primary endpoints of SVR and histological improvement in another Phase III trial for HCV (see BioCentury Extra, Wednesday Dec. 14, 2005). ...